logo-loader
viewAstraZeneca

AstraZeneca is still not converting top-line momentum into cash-flow, says UBS

Astra has affected a “momentous turnaround” in sales growth, but it has struggled to turn that top-line momentum into cash flow, according to UBS

Astrazeneca flags
UBS has downgraded Astra to ‘sell’ and cut its target price to 5,400p

AstraZeneca PLC (LON:AZN) has been downgraded to a ‘sell’ by analysts at UBS, who claim the drugs giant’s cash generation isn’t befitting of a company with an enterprise value of almost US$120bn.

Last week, the FTSE 100 group came to market with a US$3.5bn placing – the largest so far this year by a British company.

READ: AstraZeneca launches UK’s biggest cash call of 2019

Around US$1.4bn of that will be used to fund a cancer collaboration with Japanese group Daiichi Sankyo.

The rest will be used for “general corporate purposes”, including restructuring debt, which UBS reckons is a sign that Astra is struggling to convert its top-line momentum into cash flow.

“The equity raise (US$3.5bn) that went with the license deal is also aimed at refinancing near term debt, a reflection of ongoing limited cash generation in the near term and a sign of slow margin recovery,” read a note to clients.

“We estimate free cash flow of >US$8bn is required by '23 to support a current EV of US$119bn (on a sector yield), a number we can't see AZN delivering.

“We downgrade to ‘sell’ (from ‘neutral’) [and] our price target falls to 5,400p from 5,900p after scrubbing the model/CF and updating for the deal.”

Investors can’t bet on cancer success

The analysts add that Astra is trading on a forward enterprise value/ EBITDA multiple of 18x, compared to the sector average of around 10x.

“At the current valuation, the market assigns perpetuity-like positioning to the key oncology franchises, despite oncology being fast-moving and highly competitive.”

Astra shares fell 1.1% to 6,101p in mid-morning trade on Tuesday.

Quick facts: AstraZeneca

Price: 8427 GBX

LSE:AZN
Market: LSE
Market Cap: £110.58 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Xpediator PLC's CFO Robert Ross and COO of Logistics Romania to step up as...

Xpediator PLC's (LON:XPD) CFO Robert Ross speaks to Proactive's Andrew Scott following the news chief executive Stephen Blyth will step down from the position. Blyth will continue as a director in the position of founder and non-executive deputy chairman. While the search for a permanent...

1 day, 7 hours ago

2 min read